menu
    • menu

    Find Citric Acid manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    26

    API Suppliers

    9

    USDMF

    1

    CEP/COS

    4

    JDMF

    2

    EU WC

    0

    KDMF

    2

    NDC API

    0

    VMF

    11

    Listed Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    1

    EDQM

    1

    USP

    0

    JP

    4

    Others

    FINISHED DOSAGE FORMULATIONS

    127

    FDF Dossiers

    9

    FDA Orange Book

    50

    Europe

    49

    Canada

    10

    Australia

    7

    South Africa

    2

    Listed Dossiers

    1PROSPECTS

    45DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    250RELATED EXCIPIENT COMPANIES

    420EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    10

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    36,520,779

    Annual Reports

    NA

    Regulatory FDF Prices

    MARKET PLACE

    30

    API

    1

    FDF

    DIGITAL CONTENT

    3

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    23

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 77-92-9, 2-hydroxypropane-1,2,3-tricarboxylic acid, Citric acid, anhydrous, Aciletten, Anhydrous citric acid, Citro
    Molecular Formula
    C6H8O7
    Molecular Weight
    192.12  g/mol
    InChI Key
    KRKNYBCHXYNGOX-UHFFFAOYSA-N
    FDA UNII
    XF417D3PSL
    Citric Acid
    A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
    Anhydrous citric acid is a Calculi Dissolution Agent and Anti-coagulant. The mechanism of action of anhydrous citric acid is as an Acidifying Activity and Calcium Chelating Activity. The physiologic effect of anhydrous citric acid is by means of Decreased Coagulation Factor Activity.
    1 2D Structure

    Citric Acid

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-hydroxypropane-1,2,3-tricarboxylic acid
    2.1.2 InChI
    InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
    2.1.3 InChI Key
    KRKNYBCHXYNGOX-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C(C(=O)O)C(CC(=O)O)(C(=O)O)O
    2.2 Other Identifiers
    2.2.1 UNII
    XF417D3PSL
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Anhydrous Citric Acid

    2. Citrate

    3. Citric Acid Monohydrate

    4. Citric Acid, Anhydrous

    5. Uralyt U

    2.3.2 Depositor-Supplied Synonyms

    1. 77-92-9

    2. 2-hydroxypropane-1,2,3-tricarboxylic Acid

    3. Citric Acid, Anhydrous

    4. Aciletten

    5. Anhydrous Citric Acid

    6. Citro

    7. Citretten

    8. Chemfill

    9. Hydrocerol A

    10. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-

    11. Citric Acid Anhydrous

    12. Kyselina Citronova

    13. 2-hydroxy-1,2,3-propanetricarboxylic Acid

    14. 2-hydroxytricarballylic Acid

    15. Caswell No. 221c

    16. 3-carboxy-3-hydroxypentane-1,5-dioic Acid

    17. Fema No. 2306

    18. F 0001 (polycarboxylic Acid)

    19. 2-hydroxypropanetricarboxylic Acid

    20. Fema Number 2306

    21. K-lyte

    22. Kyselina Citronova [czech]

    23. K-lyte Ds

    24. Citric Acid,anhydrous

    25. Ccris 3292

    26. Hsdb 911

    27. Epa Pesticide Chemical Code 021801

    28. Citricum Acidum

    29. Citric Acid Monoglyceride

    30. Uro-trainer

    31. Ai3-06286

    32. Suby G

    33. Nsc 30279

    34. Nsc 626579

    35. Brn 0782061

    36. Mfcd00011669

    37. Nsc-30279

    38. Nsc-626579

    39. Chembl1261

    40. Xf417d3psl

    41. Kyselina 2-hydroxy-1,2,3-propantrikarbonova [czech]

    42. Kyselina 2-hydroxy-1,2,3-propantrikarbonova

    43. Chebi:30769

    44. .beta.-hydroxytricarballylic Acid

    45. Citr

    46. Nsc30279

    47. Nsc626579

    48. Nsc-112226

    49. Citric Acid Bp

    50. Citric Acid, 99%

    51. Ncgc00090954-03

    52. E330

    53. 2-hydroxy-1,2,3-propanetricarboxyic Acid

    54. Citric Acid,hydrous

    55. Dsstox_cid_332

    56. E 330

    57. Beta-hydroxytricarballylic Acid

    58. Citric Acid, Hydrous

    59. Citrate Anion

    60. Dsstox_rid_75520

    61. Dsstox_gsid_20332

    62. 141633-96-7

    63. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Homopolymer

    64. Ins No.330

    65. Citric Acid [usan:jan]

    66. Cas-77-92-9

    67. Ins-330

    68. 1,3-propanetricarboxylic Acid, 2-hydroxy-

    69. 10402-15-0

    70. Einecs 201-069-1

    71. Unii-xf417d3psl

    72. E-330

    73. Citraclean

    74. Citronensaeure

    75. Acidum Citricum

    76. Citric-acid

    77. Anhydrous Citrate

    78. 2fwp

    79. 4aci

    80. 4nrm

    81. H3cit

    82. Citric Acid, Anhydrous [usp:jan]

    83. Citric Acid,(s)

    84. Citric Acid (8ci)

    85. K-lyte (salt/mix)

    86. 1i2s

    87. 1o4l

    88. 1rq2

    89. 1y4a

    90. 2bo4

    91. 2c4v

    92. 2fw6

    93. 4to8

    94. Citraclean (salt/mix)

    95. Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-hydroxy-, C14-18-alkyl Ethers

    96. Citric Acid-[13c6]

    97. Citric Acid (anhydrous)

    98. Spectrum3_001850

    99. Wln: Qv1xqvq1vq

    100. Beta-hydroxytricarballylate

    101. Cid_311

    102. K-lyte/cl (salt/mix)

    103. Citric Acid [mi]

    104. K-lyte Ds (salt/mix)

    105. Acidum Citricum Monohydrate

    106. Bmse000076

    107. Hoc(ch2cooh)2cooh

    108. Ec 201-069-1

    109. Citric Acid [fhfi]

    110. Citric Acid [hsdb]

    111. Ncistruc1_000057

    112. Ncistruc2_000099

    113. Nciopen2_004062

    114. Nciopen2_004502

    115. Oprea1_502996

    116. Bspbio_003240

    117. Citric Acid Anhydrous (jan)

    118. 4-03-00-01272 (beilstein Handbook Reference)

    119. Citric Acid, Anhydrous, Usp

    120. Mls001066346

    121. Citric Acid [who-dd]

    122. Citric Acid (fragrance Grade)

    123. Citric Acid, Anhydrous (usp)

    124. Citricum Acidum [hpus]

    125. Anhydrous Citric Acid (jp17)

    126. Gtpl2478

    127. Citric Acid (industrial Grade)

    128. Citric Acid, Analytical Standard

    129. Dtxsid3020332

    130. Bdbm14672

    131. Citric Acid, P.a., 99.5%

    132. Kbio3_002740

    133. 4o61

    134. Citric Acid 5% Solution In Water

    135. Citric Acid, Electrophoresis Grade

    136. Hms1787n01

    137. Hms2268b04

    138. Pharmakon1600-01300013

    139. Zinc895081

    140. Anhydrous Citric Acid [ii]

    141. Anhydrous Citric Acid [jan]

    142. Citric Acid 10% Solution In Water

    143. Hy-n1428

    144. Str12052

    145. Tox21_113436

    146. Tox21_202405

    147. Tox21_300124

    148. Bbl002530

    149. Nsc759606

    150. S5761

    151. Stk286098

    152. Citric Acid,anhydrous [vandf]

    153. Akos000119911

    154. Anhydrous Citric Acid [mart.]

    155. Citric Acid, Lr, Anhydrous, >=99%

    156. 2-hydroxy-1,2,3-propanetricarboxylate

    157. Acidum Citricum [who-ip Latin]

    158. Cs-6965

    159. Db04272

    160. 3-carboxy-3-hydroxypentane-1,5-dioate

    161. Citric Acid, >=99.5%, Fcc, Fg

    162. Citric Acid, Acs Reagent, >=99.5%

    163. Citric Acid, Anhydrous Powder, A.c.s.

    164. 2-hydroxy-1,3-propanetricarboxylic Acid

    165. Citric Acid, Anhydrous [who-ip]

    166. Ncgc00090954-01

    167. Ncgc00090954-02

    168. Ncgc00090954-04

    169. Ncgc00090954-05

    170. Ncgc00254055-01

    171. Ncgc00259954-01

    172. 2-hydroxypropane-1,2,3-tricarboxylicacid

    173. Bp-31028

    174. Citric Acid, Anhydrous Granular, A.c.s.

    175. Nci60_022579

    176. Smr000471840

    177. Citric Acid 50% Solution In Water (w/w)

    178. Sbi-0206765.p001

    179. Citric Acid, Saj First Grade, >=99.5%

    180. 2-hydroxy-1,2,3-propane Tricarboxylic Acid

    181. 2-hydroxy-1,2,3-propanenetricarboxylic Acid

    182. Anhydrous Citric Acid [usp Monograph]

    183. B7297

    184. C1949

    185. Citric Acid, Anhydrous [ep Impurity]

    186. Citric Acid, Aqueous Solution (food Grade)

    187. Citric Acid, Vetec(tm) Reagent Grade, 99%

    188. Ft-0623957

    189. Ft-0665073

    190. Ft-0728530

    191. Citric Acid, Anhydrous [usp Impurity]

    192. Clenpiq Component Anhydrous Citric Acid

    193. C00158

    194. D00037

    195. Ae-562/40806920

    196. Anhydrous Citric Acid Component Of Clenpiq

    197. Citric Acid, Bioultra, Anhydrous, >=99.5% (t)

    198. Q159683

    199. J-520099

    200. 1,2,3-propanetricarboxylic Acid, 2-hydroxy- (9ci)

    201. Z56754862

    202. Citric Acid (monohydrate): H2o = 1 G : 1 Ml Solution

    203. Citric Acid, Certified Reference Material, Tracecert(r)

    204. Citric Acid, Meets Usp Testing Specifications, Anhydrous

    205. F2191-0222

    206. 8f5d336a-442d-434a-9fb0-e400ff74e343

    207. Citrate Standard For Ic, 1000 Mg/l, Analytical Standard

    208. 1,2,3-propanetricarboxylic Acid,2-hydroxy (citric Acid)

    209. Citric Acid, United States Pharmacopeia (usp) Reference Standard

    210. Citric Acid (constituent Of Cranberry Liquid Preparation) [dsc]

    211. Citric Acid, Anhydrous, Cell Culture Tested, Plant Cell Culture Tested

    212. Citric Acid, Anhydrous, European Pharmacopoeia (ep) Reference Standard

    213. Citric Acid, Anhydrous, Free-flowing, Redi-dri(tm), Acs Reagent, >=99.5%

    214. Citric Acid (constituent Of Garcinia Cambogia And Garcinia Indica) [dsc]

    215. Citric Acid, Anhydrous, Pharmaceutical Secondary Standard; Certified Reference Material

    216. Citric Acid, Meets Analytical Specification Of Ph. Eur., Bp, Usp, E330, Anhydrous, 99.5-100.5% (based On Anhydrous Substance)

    2.4 Create Date
    2004-09-16
    3 Chemical and Physical Properties
    Molecular Weight 192.12 g/mol
    Molecular Formula C6H8O7
    XLogP3-1.7
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count5
    Exact Mass192.02700259 g/mol
    Monoisotopic Mass192.02700259 g/mol
    Topological Polar Surface Area132 Ų
    Heavy Atom Count13
    Formal Charge0
    Complexity227
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Therapeutic Uses

    Mesh Heading: Anticoagulants, chelating Agents

    National Library of Medicine, SIS; ChemIDplus Record for Citric acid (77-92-9). Available from, as of April 17, 2006: https://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp

    /EXPL THER/ Regional citrate anticoagulation (RCA) is an effective form of anticoagulation for continuous renal replacement therapy (CRRT) in patients with contraindications to heparin. Its use has been very limited, possibly because of the need for special infusion solutions and difficult monitoring of the metabolic effects./The objective of this study was/ to investigate the safety and the feasibility of an RCA method for continuous veno-venous hemofiltration (CVVH) using commercially available replacement fluid. We evaluated 11 patients at high risk of bleeding, requiring CVVH. RCA was performed using commercially available replacement fluid solutions to maintain adequate acid-base balance. We adjusted the rate of citrate infusion to achieve a post-filter ionized calcium concentration [iCa] <0.4 mmol/L when blood flow was <250 mL/min, or <0.6 mmol/L when blood flow was >250 mL/min. When needed, we infused calcium gluconate to maintain systemic plasma [iCa] within the normal range. Twenty-nine filters ran for a total of 965.5 hr. Average filter life was 33.6+/-20.5 hr. Asymptomatic hypocalcemia was detected in 6.9% of all samples. No [iCa] values <0.9 mmol/L were observed. Hypercalcemia (1.39+/-0.05 mmol/L) occurred in 2.5% of all samples. /The authors/ observed hypernatremia (threshold 153 mmol/L) and alkalosis (threshold 7.51) in only 9.3% and 9.4% respectively of all samples, mostly concomitantly. No patient showed any signs of citrate toxicity. /They/ developed a protocol for RCA during CVVH using commercially available replacement fluid that proved safe, flexible and applicable in an Intensive Care Unit (ICU) setting.

    PMID:17417764 Cubattoli L et al; Int J Artif Organs. 30 (3): 244-52 (2007)

    It has ... been used to dissolve urinary bladder calculi, & as mild astringent.

    Troy, D.B. (Ed); Remmington The Science and Practice of Pharmacy. 21 st Edition. Lippincott Williams & Williams, Philadelphia, PA 2005, p. 1085

    Citrate ... of ... value in alleviation of chronic metabolic acidosis ... from chronic renal insufficiency or syndrome of renal tubular acidosis ... usually prescribed in form of sodium citrate and citric acid soln, USP ...

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 806

    Potassium citrate, up to 10 g daily, has been used as a potassium supplement; the potassium and sodium salts have been used, in similar dosages, as mild diuretics in humans.

    Bingham, E.; Cohrssen, B.; Powell, C.H.; Patty's Toxicology Volumes 1-9 5th ed. John Wiley & Sons. New York, N.Y. (2001)., p. 5:768

    4.2 Drug Warning

    A study of abdominal pain and severity of other side effects attributed to Picolax, a combination of citric acid, magnesium oxide and sodium picosulfate, was conducted among 267 patients, 55 of whom had inflammatory bowel disease, all of whom were given a full single dose of Picolax as preparation for radiology or endoscopy. The frequency of increased abdominal pain and severe side effects after Picolax administration was similar in the patients with inflammatory bowel disease and the patients with other colonic disorders. None of the patients with iron deficiency in whom investigations had yielded negative results reported severe side effects; this was significantly different from the proportion reporting severe side effects among the patients with inflammatory bowel disease, the irritable bowel syndrome and diverticular disease. The increase in the mean number of stools/24 hr after Picolax was lower in the patients with inflammatory bowel disease than in the other diagnostic groups. On review 2-4 wk after examination none of the patients with inflammatory bowel disease reported deterioration in their symptoms.

    McDonagh AJ et al; Br Med J 299: 776-7 (1989)

    Following the occurrence of aluminum encephalopathy in four patients with chronic renal failure, 34 azotemic patients seen during the same year and five volunteers who took varying combinations of aluminum hydroxide and an alkalinizing citrate (Shohl's) solution were studied. It was found that the four encephalopathic cases were older than the 34 azotemic patients (68 years + or - 14 standard deviation, versus 50 + or - 13, p< 0.05), had a higher mean serum aluminum value (727 ug/l + or - 320 versus 92 + or - 73, p< 0.005), had taken more aluminum hydroxide (5 g/day + or - 0.9 versus 1.6 + or - 1.8, p< 0.01), and more Shohl's solution (64 ml/day + or - 19 versus 20 + or - 29, p< 0.01). In all 38 patients the serum aluminum values correlated directly with age (p=0.01), aluminum hydroxide (p=0.001) and concomitant citrate intake (p=0.004). In the five healthy volunteers the 24 hr urinary aluminum excretion increased from a baseline of 22 ug + or - 19 standard deviation to 167 + or - 109 (p=0.05) during aluminum hydroxide intake, rising to 580 + or - 267 (p=0.01) during the simultaneous intake of citrate and aluminum hydroxide. Corresponding serum aluminum values were 11 ug/l + or - 2 standard deviation, 44 + or - 34 (p= 0.1), and 98 + or - 58 (p<0.05). Thus citrate seems to enhance aluminum absorption and may cause encephalopathy in patients with chronic renal failure, especially the elderly.

    PMID:2914409 Bakir AA et al; Clin Nephrol 31 (1): 40-4 (1989)

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anticoagulants

    Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)

    Calcium Chelating Agents

    Substances that bind to and sequester CALCIUM ions. (See all compounds classified as Calcium Chelating Agents.)

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    ANHYDROUS CITRIC ACID
    5.2.2 FDA UNII
    XF417D3PSL
    5.2.3 Pharmacological Classes
    Anti-coagulant [EPC]; Calcium Chelating Activity [MoA]; Calculi Dissolution Agent [EPC]; Decreased Coagulation Factor Activity [PE]; Acidifying Activity [MoA]
    5.3 ATC Code

    A - Alimentary tract and metabolism

    A09 - Digestives, incl. enzymes

    A09A - Digestives, incl. enzymes

    A09AB - Acid preparations

    A09AB04 - Citric acid

    5.4 Absorption, Distribution and Excretion

    /A portion/ of the circulating (mainly metabolic but also ingested) citric acid is excreted in urine, with 24-hour urine reference values between 1.5 and 3.68 mmol, corresponding to 0.29-0.71 g citric acid excreted per person per day.

    United Nations Environment Programme: OECD; Screening Information Data Sheets on Citric Acid (77-92-9) (January 1997). Available from, as of May 9, 2006: https://www.chem.unep.ch/irptc/sids/OECDSIDS/sidspub.html

    5.5 Metabolism/Metabolites

    Citric acid is a normal metabolite and an intermediate in cellular oxidative metabolism ... The acid is formed in the mitochondrion after condensation of acetate with oxaloacetate. The six-carbon acid is then successively degraded to a series of four-carbon acids, effectively accomplishing oxidation of acetate in the cell.

    Bingham, E.; Cohrssen, B.; Powell, C.H.; Patty's Toxicology Volumes 1-9 5th ed. John Wiley & Sons. New York, N.Y. (2001)., p. 5:767

    In human (as well as in animal and plant) physiology, citric acid is a very common intermediate in one of the central biochemical cycles, the Krebs or tricarboxylic acid cycle, which takes place in every cell. It completes the breakdown of pyruvate formed from glucose through glycolysis, thereby liberating carbon dioxide and a further four hydrogen atoms which are picked up by electron transport molecules. Thus, in man approximately 2 kg of citric acid are formed and metabolised every day. This physiological pathway is very well developed and capable of processing very high amounts of citric acid as long as it occurs in low concentrations.

    United Nations Environment Programme: OECD; Screening Information Data Sheets on Citric Acid (77-92-9) (January 2001). Available from, as of May 9, 2006: https://www.chem.unep.ch/irptc/sids/OECDSIDS/sidspub.html

    Citric acid in reaction with enzyme citratase /citrate lyase/ yields oxaloacetic acid & acetic acid.

    Fenaroli's Handbook of Flavor Ingredients. Volume 2. Edited, translated, and revised by T.E. Furia and N. Bellanca. 2nd ed. Cleveland: The Chemical Rubber Co., 1975., p. 785

    5.6 Mechanism of Action

    ... The NK(2), and to a lesser extent the NK(1), receptors have been shown to be involved with citric acid-induced bronchoconstriction in the guinea pig, which is in part mediated by endogenously released bradykinin. Tachykinins and bradykinin could also modulate citric acid-induced bronchoconstriction. ... Bronchoconstriction induced by citric acid inhalation in the guinea pig, mainly caused by the tachykinin NK(2) receptor, is counteracted by bronchoprotective NO after activation of bradykinin B(2) and tachykinin NK(1) receptors in airway epithelium.

    PMID:11749919 Ricciardolo FL; Am J Med 111 (Suppl 8A): 18S-24S (2001)

    ... A concentration of 47.6 mmol/L of citric acid (pH 2.3) in water led to total cell death within three minutes of incubation /with gingival fibroblasts (GF)/. Media containing 23.8 mmol/L and 47.6 mmol/L of citric acid exerted strong cytotoxicity (47 to 90 per cent of cell death) and inhibited protein synthesis (IC50 = 0.28 per cent) of GF within three hours of incubation. Incubation of cells in a medium containing 11.9 mmol/L of citric acid also suppressed the attachment and spreading of fibroblasts on culture plates and Type I collagen, with 58 per cent and 22 per cent of inhibition, respectively. Culture medium supplemented with 11.9, 23.8 and 47.6 mmol/L of citric acid also led to extracellular acidosis by decreasing the pH value from 7.5 to 6.3, 5.2 and 3.8, respectively.

    PMID:10452169 Lan WC et al; Aust Dent J 44 (2): 123-30 (1999)

    Inhalation of citric acid (CA) causes airway constriction and coughing. To investigate the role of mast cells in CA-induced airway constriction and cough, three experiments using guinea pigs were carried out. In the first experiment, /the authors/ used compound 48/80 to deplete mast cells, cromolyn sodium to stabilize mast cells, MK-886 to inhibit synthesis of leukotrienes, pyrilamine to antagonize histamine H1 receptor, methysergide to antagonize serotonin receptor, and indomethacin to inhibit cyclooxygenase. In the second experiment, compound 48/80-pretreated animals were divided into 2 parts; the first one was used to test the role of exogenous leukotriene (LT) C4, while the second one to test the role of exogenous histamine. Decreases in respiratory compliance (Crs) and forced expiratory volume in 0.1 sec (FEV0.1) were used as indicators for airway constriction in anesthetized guinea pigs. CA-induced cough was recorded for 12 min using a barometric body plethysmograph in conscious animals. In the third experiment, the activation of mast cells upon CA inhalation was investigated by determining lung tissue or arterial plasma histamine concentration in animals. Exposure to CA induced marked airway constriction and increase in cough number. Compound 48/80, cromolyn sodium, MK-886 and pyrilamine, but not indomethacin or methysergide, significantly attenuated CA-induced airway constriction and cough. Injection of LTC4 or histamine caused a significant increase in CA-induced airway constriction and cough in compound 48/80-pretreated animals. In addition, CA inhalation caused significant increase in lung tissue and plasma histamine concentrations, which were blocked by compound 48/80 pretreatment. These results suggest that mast cells play an important role in CA aerosol inhalation-induced airway constriction and cough via perhaps mediators including LTs and histamine.

    PMID:20359123 Lai YL et al; Chin J Physiol. 52 (5 Suppl): 332-8 (2009)

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - SOLUTION;IRRIGATION - 6.602GM/100ML;...DOSAGE - SOLUTION;IRRIGATION - 6.602GM/100ML;198MG/100ML;3.177GM/100ML

    USFDA APPLICATION NUMBER - 19481

    read-more

    DOSAGE - FOR SOLUTION;ORAL - 12GM/PACKET;3.5G...DOSAGE - FOR SOLUTION;ORAL - 12GM/PACKET;3.5GM/PACKET;10MG/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 202535

    read-more

    DOSAGE - SOLUTION;ORAL - 12GM/BOT;3.5GM/BOT;1...DOSAGE - SOLUTION;ORAL - 12GM/BOT;3.5GM/BOT;10MG/BOT

    USFDA APPLICATION NUMBER - 209589

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Topical

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Looking for 77-92-9 / Citric Acid API manufacturers, exporters & distributors?

    Citric Acid manufacturers, exporters & distributors 1

    88

    PharmaCompass offers a list of Citric Acid API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Citric Acid manufacturer or Citric Acid supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Citric Acid manufacturer or Citric Acid supplier.

    PharmaCompass also assists you with knowing the Citric Acid API Price utilized in the formulation of products. Citric Acid API Price is not always fixed or binding as the Citric Acid Price is obtained through a variety of data sources. The Citric Acid Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Citric Acid

    Synonyms

    77-92-9, 2-hydroxypropane-1,2,3-tricarboxylic acid, Citric acid, anhydrous, Aciletten, Anhydrous citric acid, Citro

    Cas Number

    77-92-9

    Unique Ingredient Identifier (UNII)

    XF417D3PSL

    About Citric Acid

    A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.

    2-hydroxypropane-1,2,3-tricarboxylic acid Manufacturers

    A 2-hydroxypropane-1,2,3-tricarboxylic acid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 2-hydroxypropane-1,2,3-tricarboxylic acid, including repackagers and relabelers. The FDA regulates 2-hydroxypropane-1,2,3-tricarboxylic acid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 2-hydroxypropane-1,2,3-tricarboxylic acid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of 2-hydroxypropane-1,2,3-tricarboxylic acid manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    2-hydroxypropane-1,2,3-tricarboxylic acid Suppliers

    A 2-hydroxypropane-1,2,3-tricarboxylic acid supplier is an individual or a company that provides 2-hydroxypropane-1,2,3-tricarboxylic acid active pharmaceutical ingredient (API) or 2-hydroxypropane-1,2,3-tricarboxylic acid finished formulations upon request. The 2-hydroxypropane-1,2,3-tricarboxylic acid suppliers may include 2-hydroxypropane-1,2,3-tricarboxylic acid API manufacturers, exporters, distributors and traders.

    click here to find a list of 2-hydroxypropane-1,2,3-tricarboxylic acid suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    2-hydroxypropane-1,2,3-tricarboxylic acid USDMF

    A 2-hydroxypropane-1,2,3-tricarboxylic acid DMF (Drug Master File) is a document detailing the whole manufacturing process of 2-hydroxypropane-1,2,3-tricarboxylic acid active pharmaceutical ingredient (API) in detail. Different forms of 2-hydroxypropane-1,2,3-tricarboxylic acid DMFs exist exist since differing nations have different regulations, such as 2-hydroxypropane-1,2,3-tricarboxylic acid USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A 2-hydroxypropane-1,2,3-tricarboxylic acid DMF submitted to regulatory agencies in the US is known as a USDMF. 2-hydroxypropane-1,2,3-tricarboxylic acid USDMF includes data on 2-hydroxypropane-1,2,3-tricarboxylic acid's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 2-hydroxypropane-1,2,3-tricarboxylic acid USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of 2-hydroxypropane-1,2,3-tricarboxylic acid suppliers with USDMF on PharmaCompass.

    2-hydroxypropane-1,2,3-tricarboxylic acid JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The 2-hydroxypropane-1,2,3-tricarboxylic acid Drug Master File in Japan (2-hydroxypropane-1,2,3-tricarboxylic acid JDMF) empowers 2-hydroxypropane-1,2,3-tricarboxylic acid API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the 2-hydroxypropane-1,2,3-tricarboxylic acid JDMF during the approval evaluation for pharmaceutical products. At the time of 2-hydroxypropane-1,2,3-tricarboxylic acid JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of 2-hydroxypropane-1,2,3-tricarboxylic acid suppliers with JDMF on PharmaCompass.

    2-hydroxypropane-1,2,3-tricarboxylic acid CEP

    A 2-hydroxypropane-1,2,3-tricarboxylic acid CEP of the European Pharmacopoeia monograph is often referred to as a 2-hydroxypropane-1,2,3-tricarboxylic acid Certificate of Suitability (COS). The purpose of a 2-hydroxypropane-1,2,3-tricarboxylic acid CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of 2-hydroxypropane-1,2,3-tricarboxylic acid EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of 2-hydroxypropane-1,2,3-tricarboxylic acid to their clients by showing that a 2-hydroxypropane-1,2,3-tricarboxylic acid CEP has been issued for it. The manufacturer submits a 2-hydroxypropane-1,2,3-tricarboxylic acid CEP (COS) as part of the market authorization procedure, and it takes on the role of a 2-hydroxypropane-1,2,3-tricarboxylic acid CEP holder for the record. Additionally, the data presented in the 2-hydroxypropane-1,2,3-tricarboxylic acid CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the 2-hydroxypropane-1,2,3-tricarboxylic acid DMF.

    A 2-hydroxypropane-1,2,3-tricarboxylic acid CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. 2-hydroxypropane-1,2,3-tricarboxylic acid CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of 2-hydroxypropane-1,2,3-tricarboxylic acid suppliers with CEP (COS) on PharmaCompass.

    2-hydroxypropane-1,2,3-tricarboxylic acid WC

    A 2-hydroxypropane-1,2,3-tricarboxylic acid written confirmation (2-hydroxypropane-1,2,3-tricarboxylic acid WC) is an official document issued by a regulatory agency to a 2-hydroxypropane-1,2,3-tricarboxylic acid manufacturer, verifying that the manufacturing facility of a 2-hydroxypropane-1,2,3-tricarboxylic acid active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 2-hydroxypropane-1,2,3-tricarboxylic acid APIs or 2-hydroxypropane-1,2,3-tricarboxylic acid finished pharmaceutical products to another nation, regulatory agencies frequently require a 2-hydroxypropane-1,2,3-tricarboxylic acid WC (written confirmation) as part of the regulatory process.

    click here to find a list of 2-hydroxypropane-1,2,3-tricarboxylic acid suppliers with Written Confirmation (WC) on PharmaCompass.

    2-hydroxypropane-1,2,3-tricarboxylic acid NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 2-hydroxypropane-1,2,3-tricarboxylic acid as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for 2-hydroxypropane-1,2,3-tricarboxylic acid API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture 2-hydroxypropane-1,2,3-tricarboxylic acid as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain 2-hydroxypropane-1,2,3-tricarboxylic acid and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 2-hydroxypropane-1,2,3-tricarboxylic acid NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of 2-hydroxypropane-1,2,3-tricarboxylic acid suppliers with NDC on PharmaCompass.

    2-hydroxypropane-1,2,3-tricarboxylic acid GMP

    2-hydroxypropane-1,2,3-tricarboxylic acid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of 2-hydroxypropane-1,2,3-tricarboxylic acid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 2-hydroxypropane-1,2,3-tricarboxylic acid GMP manufacturer or 2-hydroxypropane-1,2,3-tricarboxylic acid GMP API supplier for your needs.

    2-hydroxypropane-1,2,3-tricarboxylic acid CoA

    A 2-hydroxypropane-1,2,3-tricarboxylic acid CoA (Certificate of Analysis) is a formal document that attests to 2-hydroxypropane-1,2,3-tricarboxylic acid's compliance with 2-hydroxypropane-1,2,3-tricarboxylic acid specifications and serves as a tool for batch-level quality control.

    2-hydroxypropane-1,2,3-tricarboxylic acid CoA mostly includes findings from lab analyses of a specific batch. For each 2-hydroxypropane-1,2,3-tricarboxylic acid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    2-hydroxypropane-1,2,3-tricarboxylic acid may be tested according to a variety of international standards, such as European Pharmacopoeia (2-hydroxypropane-1,2,3-tricarboxylic acid EP), 2-hydroxypropane-1,2,3-tricarboxylic acid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (2-hydroxypropane-1,2,3-tricarboxylic acid USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search